Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? (Q30442979)

21 June 2017

1 reference

title

Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? (English)

1 reference

21 June 2017

1

Anita H Clayton

1 reference

PubMed ID

17309340

21 June 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Pharmacotherapy

21 June 2017

1 reference

21 June 2017

8

1 reference

21 June 2017

4

1 reference

21 June 2017

457-466

1 reference

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

21 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Steady-state pharmacokinetics of bupropion SR in juvenile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Safety profile of sustained-release bupropion in depression: results of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Antidepressants and seizures: emphasis on newer agents and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

Bupropion in Tricyclic Antidepressant Nonresponders with Unipolar Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.457

21 January 2018

Identifiers

DOI

10.1517/14656566.8.4.457

1 reference

21 June 2017

1 reference

PubMed ID

17309340